Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its peers? We will compare Salix Pharmaceuticals to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Salix Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A -26.55
Salix Pharmaceuticals Competitors $3.02 billion $642.98 million -27.27

Salix Pharmaceuticals’ peers have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Salix Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
Salix Pharmaceuticals Competitors -540.77% -43.51% -23.03%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Salix Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
Salix Pharmaceuticals Competitors 69 339 989 29 2.69

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 24.29%. Given Salix Pharmaceuticals’ peers higher possible upside, analysts plainly believe Salix Pharmaceuticals has less favorable growth aspects than its peers.

Insider & Institutional Ownership

64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Salix Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ peers have a beta of 1.54, indicating that their average share price is 54% more volatile than the S&P 500.

Summary

Salix Pharmaceuticals peers beat Salix Pharmaceuticals on 8 of the 8 factors compared.

About Salix Pharmaceuticals

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive News & Stock Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.